Stocks · News reference
HC Wainwright & Co. analyst Yi Chen downgrades EyePoint (NASDAQ:EYPT) from Buy to Neutral.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
EyePoint Inc. (NASDAQ: EYPT) announced disappointing Phase 3 clinical trial results for DURAVYU on August 17, 2026, failing to meet its primary endpoint in the LUGANO trial for wet age-related macular degeneration treatment. The stock subsequently dropped over 66%, prompting a securities litigation investigation by KTMC on behalf of affected investors.
Wall Street analysts changed outlook on top companies. Check out complete rating changes, including upgrades/downgrades, on our page.
EyePoint, Inc. (EYPT) announced its participation in three major investor conferences in September 2026, including Citi Biopharma, Cantor Global Healthcare, and Morgan Stanley Global Healthcare conferences. The company will also present multiple scientific presentations at The Retina Society's 59th Annual Scientific Meeting, focusing on its lead product candidate DURAVYU (vorolanib intravitreal insert) for retinal diseases, including Phase 3 trial data for wet AMD treatment.